Regulatory Approval - England's drug pricing regulator recommended GSK's HIV prevention injection [1] Pharmaceutical Innovation - The recommendation makes it the first long-acting pre-exposure treatment for use within the National Health Service [1]

HIV Prevention Breakthrough - A new injectable medicine, Tuggo, represents a potential milestone in HIV prevention [1] - Tuggo is a first-of-its-kind medicine for preventing HIV, administered only twice a year [2] - Clinical trials showed almost 100% protection against HIV with the injectable [2] - The injectable is the result of 20 years of work by Gilead scientists [2] Compliance and Efficacy - Pill-based HIV prevention faces compliance challenges, with only about 50% of people taking pills being compliant [3] - CDC data indicates only about one-third of the population defined by CDC are compliant with pill-based medicine [3] - Non-compliance with pills can lead to breakthrough cases of HIV [4] - The twice-a-year injectable aims to improve prevention by meeting people where they are in terms of adherence [4]